AKT - CHEMOTHERAPY MV (produced by Ruby Ibarra)

(4:9)

Addressing the Mechanism of Action for the AKT Pathway in TNBC

(1:10)

Insights into the future of AKT inhibitors combination with chemotherapies for aTNBC

(45)

The protein RRP9 promotes gemcitabine resistance in pancreatic cancer by activating the AKT pathway

(1:57)

MK-2206 dihydrochloride: A Promising AKT Inhibitor for Cancer Therapy and Beyond | GlpBio

(2:12)

AKT inhibitors in research and application

(8:54)

Partly by parthanatos: A new view of how AKT inhibitors kill cancer cells

(1:37)

The prevention of antigen escape in B-cell lymphomas treated with bispecific antibodies

(3:15)

Intra Arterial Chemotherapy (IAC) for Retinoblastoma

(7:50)

FDA Approved AKT Inhibitor for Patients With Advanced HR-Positive Breast Cancer

(4:41)

Transcending the Limits of Chemotherapy: Novel Strategies to Treat Meningiomas

(26:25)

BARBICAN: ipatasertib plus atezolizumab and chemotherapy in TNBC

(3:45)

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant Therapy

(27:3)

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

(25:14)

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

(1:39)

IMPAKT 2013: The future of PI3K/AKT/mTOR inhibitors in breast cancer

(11:11)

How prevalent are AKT Pathway alterations in breast cancer?

(49)

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

(1:)

What is the chemotherapy used during an ASCT? Are there other options? #myeloma

(4:16)